Strategic Acquisition Amaryllis Nucleics was acquired by Active Motif in January 2022, indicating a potential alignment of RNA sequencing capabilities with epigenetics-focused precision medicine. This suggests opportunities to engage Active Motif’s broader customer base or leverage combined offerings for joint selling in oncology and related fields.

Integrated Portfolio Post-acquisition, Amaryllis’ RNA sequencing services and 3' DGE RNA Library Prep Kit are positioned within Active Motif’s portfolio, signaling a path to cross-sell to Active Motif’s customers who seek integrated epigenetics and transcriptomics workflows.

Low Footprint With a very small team (0-1 employees reported) prior to acquisition and revenue under one million, there may be lean operations and high potential for scalability through partner-led, channel, or OEM strategies rather than pure in-house expansion.

Early Innovation Historically, Amaryllis launched dual purpose RNA-seq kits enabling full-transcript or 3′-DGE libraries from a single kit, signaling a track record of rapid productization and a blueprint for future modular offerings that can attract research institutions and biotechs seeking flexible RNaseq solutions.

Targeted Markets Located in the Bay Area with a focus on cancer diagnostics, pharmaceutical development, and genomics research, Amaryllis’ capabilities align with high-value segments that typically engage early adopter laboratories, contract research organizations, and pharma collaborators looking to accelerate sequencing timelines and reduce costs.